

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA

NATURAL ALTERNATIVES
INTERNATIONAL, INC.,

Plaintiff,

v.

CREATIVE COMPOUNDS, INC.,

Defendant.

Case No.: 15cv2081 JM (AGS)

**ORDER DENYING DEFENDANT’S
MOTION TO CONSOLIDATE**

Defendant Creative Compounds, Inc. (“Creative”) moves the court to consolidate two actions involving it and Plaintiff Natural Alternatives International, Inc. (“NAI”). (Doc. No. 60.) NAI opposes consolidation. (Doc. No. 64.) For the following reasons, the court denies Creative’s motion.

BACKGROUND

A. Parties

NAI is a formulator, manufacturer, marketer, and supplier of nutritional supplements that sells its branded CarnoSyn® beta alanine to customers around the world. NAI owns several patents and trademarks on its products. Creative is an importer and supplier of generic beta alanine to nutritional supplement contract manufacturers, formulators, and distributors in the United States. NAI and Creative are competitors.

1 **B. Procedural History**

2 On September 18, 2015, NAI filed suit against Creative in this court (case number
3 15cv2081, hereinafter “the Lanham Act case”). In the Lanham Act case, NAI alleges
4 various false advertising, trade libel, and unfair competition claims under the Lanham Act
5 and state and common law. The Lanham Act case is based on a blast email Creative sent
6 to its customers in September 2015. NAI alleges that the email included
7 misrepresentations regarding NAI’s beta alanine product, CarnoSyn®, including that
8 (1) Creative could offer the trademarked beta alanine product to customers at a discount;
9 (2) NAI unlawfully uses its patents to keep prices of the trademarked beta alanine high;
10 and (3) NAI “appears to have admitted” that three of its patents are invalid, “as construed
11 by a court in Delaware in 2011.”

12 On August 24, 2016, NAI filed another action against Creative (case number
13 16cv2146, hereinafter “the Patent case”). The Patent case was originally assigned to
14 Judge Curiel, but was transferred to this court on October 12, 2016, pursuant to the
15 district’s low-number rule. In the Patent case, NAI alleges Creative induced others to
16 infringe, and contributed to the infringement of, U.S. Patent No. 7,825,084. NAI asserts
17 that Creative infringed its patent “through the sale of beta-alanine and statements made in
18 the Blast Email.” The claims in the Patent case appear to be almost entirely based on the
19 same blast email that is at issue in the Lanham Act case, but the complaint in the Patent
20 case also more generally alleges that Creative infringed the patent through “the sale of
21 beta-alanine.”

22 Creative now moves to consolidate the two cases and requests a new scheduling
23 order that will govern both cases and effectively reset all deadlines.

24 **C. Status of Discovery**

25 The parties have undertaken significant discovery in the Lanham Act case. On
26 February 11, 2016, Magistrate Judge Brooks entered a scheduling order requiring the
27 parties to serve written discovery requests by August 22, 2016, and to complete fact
28

1 discovery by October 17, 2016. The parties exchanged their Rule 26(a)(1) initial
2 disclosures on April 1.

3 NAI served Creative with written discovery requests on April 5, July 19, and
4 August 2, 3, 12, and 22. NAI has served Rule 30(b)(6) deposition notices on Creative
5 and has taken the deposition of Creative's designated witnesses on the subject of
6 document collection. NAI has also served personal deposition notices on Creative
7 employees and subpoenas for depositions on third parties.

8 By contrast, Creative did not serve any written discovery requests on NAI by the
9 August 22 deadline. Creative filed an ex parte motion for leave to serve discovery
10 requests past that deadline, which Judge Brooks denied. Creative has now served
11 deposition notices on NAI employees and a 69-topic Rule 30(b)(6) deposition notice on
12 NAI. The notices contain requests to produce documents.

13 Both parties have filed motions for protective orders regarding a number of
14 scheduled depositions and corresponding document requests. Judge Brooks stayed the
15 depositions pending the resolution of the motions for protective orders. Both cases have
16 since been transferred to Magistrate Judge Schopler, who set a hearing on the motions for
17 protective orders in the Lanham Act case for November 21, 2016.

18 **D. Remaining Schedules**

19 In the Lanham Act case, the scheduling order directs the parties to: disclose experts
20 by November 14, 2016; serve opening expert reports by January 9, 2017; serve rebuttal
21 expert reports by January 27, 2017; complete all expert discovery by February 27, 2017;
22 and file pretrial motions by March 27, 2017. Trial is set for September 18, 2017. In the
23 Patent case, an ENE is set for December 12, 2106. No other schedules are set.

24 **LEGAL STANDARDS**

25 When actions "involve a common question of law or fact," courts may
26 "consolidate the actions" or "issue any other orders to avoid unnecessary cost or delay."
27 Fed. R. Civ. P. 42(a). "The district court has broad discretion under this rule to
28 consolidate cases pending in the same district." Inv'rs Research Co. v. U.S. Dist. Court

1 for Cent. Dist. of California, 877 F.2d 777, 777 (9th Cir. 1989). In determining whether
2 consolidation is appropriate, courts weigh “the interest of judicial convenience against the
3 potential for delay, confusion, and prejudice caused by consolidation.” Southwest
4 Marine, Inc., v. Triple A. Mach. Shop, Inc., 720 F. Supp. 805, 807 (N.D. Cal. 1989).

5 **DISCUSSION**

6 Creative makes several arguments in favor of consolidation, including that (1) the
7 parties are identical; (2) the claims in both cases primarily arise out of the same blast
8 email (and thus the factual portions of the complaints are nearly identical); (3) there is
9 judicial economy in having a single trial based on an overlapping set of facts; (4) any
10 delay is NAI’s own fault, because it could have brought its patent claims in its original
11 action; and (5) maintaining separate cases “increases the work required by the courts,
12 increases the cost of the actions, requires more work by the parties and the courts, and
13 unfairly burdens third party recipients of the September 2015 email.”¹

14 In response, NAI makes the following arguments against consolidation: (1) the
15 Lanham Act case is much further along, with only the depositions that are the subject of
16 the parties’ motions for protective orders left to be completed; (2) the court should not
17 give Creative another opportunity to serve written discovery in the Lanham Act case after
18 it failed to do so by the deadline; (3) resolving the Patent case has no bearing on the
19

20
21 ¹ Creative makes a number of additional arguments that the court finds unpersuasive.
22 First, Creative argues that “if through the Patent Case, Creative shows that the patent-in-
23 suit is invalid, or that the 2015 email did not induce infringement, then such
24 determination may significantly impact the disposition of the claims asserted in the
25 Lanham Act Case.” As NAI points out, however, even if Creative were to successfully
26 invalidate NAI’s patents now, that would not necessarily justify Creative’s statements at
27 the time of the blast email. Second, Creative argues that the local patent rules allow for
28 discovery that may be useful to its defense in the Lanham Act case, as well as the Patent
Case. But the opportunity to manipulate the patent rules to better defend non-patent
claims is not a good argument for consolidation. Finally, Creative argues that
consolidating the cases eliminates the possibility that two judges will decide two similar
situations differently. Now that both cases are in this court, that is no longer an issue.

1 Lanham Act case because at “the time Creative sent the Blast Email (which is still true
2 today), none of NAI’s 14 U.S. patents had been held invalid by a court and, by statute,
3 they were presumed valid,” or put another way, Creative’s claims were improper at the
4 time they were made and no future result in the Patent case would change that; (4) the
5 Patent case will involve much broader issues related to proof of infringement and
6 Creative’s defenses because NAI asserts the blast email as “only some evidence of past
7 and ongoing infringement by Creative and multiple additional parties, i.e., Creative’s
8 customers (named in the [Patent] complaint as DOES 1–100)”; and (5) NAI is seeking
9 injunctive relief in the Lanham Act case, including corrective disclosures by Creative to
10 the beta alanine market, and delaying such relief would prejudice NAI.

11 The court recognizes that there are reasonable arguments on both sides and
12 understands the appeal of having all claims consolidated in one action. But because the
13 cases are at very different junctures, the court believes it is most sensible to maintain
14 them as separate actions. Courts set deadlines for a reason, and whenever possible, this
15 court adheres to those deadlines. Consolidating the cases at this point will have the effect
16 of delaying the Lanham Act case for upwards of a year.


17 At the same time, though, the court is willing to look for opportunities to
18 coordinate the proceedings in an effort to prevent the duplication of work and promote
19 judicial economy. The court will undertake that objective on its own initiative and
20 invites the parties to propose their own ideas with an eye towards that goal, as well.

21 CONCLUSION

22 In sum, the court denies Creative’s motion to consolidate.

23 IT IS SO ORDERED.

24 DATED: November 7, 2016

25 
26 _____
27 JEFFREY T. MULLER
28 United States District Judge